Genome-wide quantification of copy-number aberration impact on gene expression in ovarian high-grade serous carcinoma

dc.contributor.authorJamalzadeh Sanaz
dc.contributor.authorDai Jun
dc.contributor.authorLavikka Kari
dc.contributor.authorLi Yilin
dc.contributor.authorJiang Jing
dc.contributor.authorHuhtinen Kaisa
dc.contributor.authorVirtanen Anni
dc.contributor.authorOikkonen Jaana
dc.contributor.authorHietanen Sakari
dc.contributor.authorHynninen Johanna
dc.contributor.authorVähärautio Anna
dc.contributor.authorHäkkinen Antti
dc.contributor.authorHautaniemi Sampsa
dc.contributor.organizationfi=biolääketieteen laitos|en=Institute of Biomedicine|
dc.contributor.organizationfi=synnytys- ja naistentautioppi|en=Obstetrics and Gynaecology|
dc.contributor.organizationfi=tyks, vsshp|en=tyks, varha|
dc.contributor.organization-code1.2.246.10.2458963.20.74725736230
dc.contributor.organization-code1.2.246.10.2458963.20.77952289591
dc.converis.publication-id387072749
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/387072749
dc.date.accessioned2025-08-27T22:48:02Z
dc.date.available2025-08-27T22:48:02Z
dc.description.abstractCopy-number alterations (CNAs) are a hallmark of cancer and can regulate cancer cell states via altered gene expression values. Herein, we have developed a copy-number impact (CNI) analysis method that quantifies the degree to which a gene expression value is impacted by CNAs and leveraged this analysis at the pathway level. Our results show that a high CNA is not necessarily reflected at the gene expression level, and our method is capable of detecting genes and pathways whose activity is strongly influenced by CNAs. Furthermore, the CNI analysis enables unbiased categorization of CNA categories, such as deletions and amplifications. We identified six CNI-driven pathways associated with poor treatment response in ovarian high-grade serous carcinoma (HGSC), which we found to be the most CNA-driven cancer across 14 cancer types. The key driver in most of these pathways was amplified wild-type KRAS, which we validated functionally using CRISPR modulation. Our results suggest that wild-type KRAS amplification is a driver of chemotherapy resistance in HGSC and may serve as a potential treatment target.
dc.identifier.eissn1471-2407
dc.identifier.jour-issn1471-2407
dc.identifier.olddbid202828
dc.identifier.oldhandle10024/185855
dc.identifier.urihttps://www.utupub.fi/handle/11111/48883
dc.identifier.urlhttps://bmccancer.biomedcentral.com/articles/10.1186/s12885-024-11895-6
dc.identifier.urnURN:NBN:fi-fe2025082785863
dc.language.isoen
dc.okm.affiliatedauthorHuhtinen, Kaisa
dc.okm.affiliatedauthorHietanen, Sakari
dc.okm.affiliatedauthorHynninen, Johanna
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline3122 Cancersen_GB
dc.okm.discipline3123 Gynaecology and paediatricsen_GB
dc.okm.discipline3122 Syöpätauditfi_FI
dc.okm.discipline3123 Naisten- ja lastentauditfi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherBioMed Central
dc.publisher.countryUnited Kingdomen_GB
dc.publisher.countryBritanniafi_FI
dc.publisher.country-codeGB
dc.relation.articlenumber173
dc.relation.doi10.1186/s12885-024-11895-6
dc.relation.ispartofjournalBMC Cancer
dc.relation.issue1
dc.relation.volume24
dc.source.identifierhttps://www.utupub.fi/handle/10024/185855
dc.titleGenome-wide quantification of copy-number aberration impact on gene expression in ovarian high-grade serous carcinoma
dc.year.issued2024

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
s12885-024-11895-6.pdf
Size:
5.17 MB
Format:
Adobe Portable Document Format